Get all your news in one place.
100's of premium titles.
One app.
Start reading
Reuters
Reuters
Business

Relief Therapeutics says Zyesami to be included in COVID-19 clinical trial

Relief Therapeutics said its partner NeuroRx and the Quantum Leap Healthcare Collaborative signed an agreement to include Zyesami in the I-SPY COVID-19 clinical trial, a platform trial assessing multiple drugs for critically ill COVID-19 patients.

Zyesami will be included as one of the first drugs targeting respiratory failure in critically ill COVID-19 patients, Relief Therapeutics said in a statement on Monday.

(Reporting by Silke Koltrowitz; editing by Thomas Seythal)

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.